Strategic Move Towards Portfolio Diversification and IPO

LEO Pharma has acquired global rights to dersimelagon, an innovative drug candidate for rare skin diseases, from Mitsubishi Tanabe Pharma, a portfolio company of Bain Capital. This acquisition is strategically timed as LEO Pharma prepares for an Initial Public Offering (IPO) on the Copenhagen Stock Exchange, aiming to enhance the immediate commercial potential of its pipeline. Following last year's partnership with Boehringer Ingelheim for Spevigo and the acquisition of Replay, a gene therapy company, in April of this year, LEO Pharma is rapidly strengthening its portfolio in the rare dermatology area. This positions the privately held company to evolve from a traditional chronic skin disease player into a leading player in the high-value rare disease market, driving significant growth.

Securing Significant Clinical Convenience as an Oral Medication

Dersimelagon is an innovative, once-daily oral melanocortin 1 receptor agonist (MC1R Agonist) candidate. It is being developed to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), conditions that cause severe burning pain and liver damage upon sun exposure. A Phase 3 clinical trial, the results of which were announced earlier this year, demonstrated significant efficacy in increasing patients' tolerance to sun exposure and reducing pain frequency. Notably, it offers a dramatic improvement in patient convenience compared to Scenesse, the only existing standard treatment that requires hospital visits every two months for subcutaneous implantation. This enhanced convenience positions dersimelagon as a powerful asset that could significantly disrupt the market upon commercialization.

High Unmet Need and Growth Potential in the Rare Skin Disease Market

The global market for EPP treatment is currently estimated at $163 million to $320 million and is projected to grow to $540 million by 2034, representing a high-margin niche market. Clinuvel Pharmaceuticals' Scenesse has enjoyed a dominant position with approximately $70 million in annual sales, but its market penetration has been limited by the challenges of an implantable treatment. The introduction of dersimelagon is expected to rapidly address the latent market demand by attracting patients who are reluctant to use or have limited access to existing treatments. The combination of a potentially high pricing flexibility inherent in rare diseases and the significant advantage of oral administration suggests a strong potential for dersimelagon to rapidly reshape the competitive landscape.

Early Resolution of Regulatory Risk with Completion of New Drug Application

The fact that Mitsubishi Tanabe Pharma has already submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in June 2026 signals a virtual end to the uncertainties of the clinical development phase. Having already received Fast Track and Orphan Drug designations from the U.S. FDA, the drug is eligible for various regulatory support measures, including accelerated review and tax benefits. This creates optimal conditions for LEO Pharma to minimize research and development (R&D) risk and recognize commercial revenue in the short term. If the review process proceeds smoothly, approval is likely by next year, which is expected to contribute immediately to improved short- and medium-term financial performance.